Advanced Urothelial Carcinoma
Advanced Urothelial Carcinoma
Advertisement
Zachary BessetteASCO 2023 | June 2, 2023
A post hoc analysis of the IMvigor130 trial examined OS outcomes during first-line induction for patients with mUC.
Read More
Emily MenendezASCO 2023 | June 1, 2023
A post-hoc exploratory analysis of the KEYNOTE-361 study was presented at the 2023 ASCO annual meeting.
Arnab Basu, MD, MPH, FACPAdvanced Urothelial Carcinoma | June 1, 2023
Drs. Koshkin and Basu comment on the best available treatment approach for patients with ctDNA-positive MIBC after surgery.
Arnab Basu, MD, MPH, FACPAdvanced Urothelial Carcinoma | June 1, 2023
Drs. Koshkin, Basu break down treatment considerations based on ctDNA status after radical cystectomy, among other factors.
Arnab Basu, MD, MPH, FACPAdvanced Urothelial Carcinoma | June 1, 2023
Drs. Koshkin and Basu discuss how ctDNA are being evaluated for disease recurrence, response monitoring in advanced UC.
Zachary BessetteASCO 2023 | May 30, 2023
EV plus pembrolizumab continues to demonstrate promising survival trends with durable responses in first-line la/mUC.
Arlene O. Siefker-Radtke, MDAdvanced Urothelial Carcinoma | May 26, 2023
Dr. Siefker-Radtke shares the novel targeted therapies for bladder cancer and how they are assessed in combinations.
Zachary BessetteASCO 2023 | May 26, 2023
Post hoc analyses from JAVELN Bladder 100 shed light on the long-term safety profile of avelumab first-line maintenance.
Jonathan E. Shoag, MDAdvanced Urothelial Carcinoma | May 25, 2023
Drs. Shoag and Zhu describe their recent analysis on the data supporting ICI use in patients with cisplatin-ineligible mUC.
Emily MenendezAdvanced Urothelial Carcinoma | May 12, 2023
After maintenance approval, an estimated 42.8% of patients received first-line ICI with either pembrolizumab or atezolizumab.
Jonathan Rosenberg, MDAdvanced Urothelial Carcinoma | May 9, 2023
Dr. Rosenberg discusses EV plus pembrolizumab, how the combination is being investigated in clinical trials, and toxicity.
Emily MenendezAdvanced Urothelial Carcinoma | May 5, 2023
Clinical trials that evaluated pembrolizumab, avelumab, and nivolumab for urothelial carcinoma were analyzed.
Zachary BessetteAUA 2023: Focus on Bladder Cancer | April 28, 2023
IMvigor210 and IMvigor211 shed light on the association between irAEs and outcomes after receiving atezolizumab for aUC.
Zachary BessetteAUA 2023: Focus on Bladder Cancer | April 28, 2023
Long-term exploratory analyses of subgroups defined by response to first-line chemotherapy in the JAVELIN Bladder 100 trial.
Elizabeth Plimack, MD, MSAdvanced Urothelial Carcinoma | April 21, 2023
Dr. Plimack discusses the results of her phase 2 study on hypomethylating agents, and gives a preview of research to come.
Elizabeth Plimack, MD, MSAdvanced Urothelial Carcinoma | April 21, 2023
Elizabeth Plimack, MD, MS, provides an overview of a recent phase 2 trial of guadecitabine plus atezolizumab for mUC.
Emily MenendezAdvanced Urothelial Carcinoma | April 14, 2023
A study carried out whole-exome sequencing on tumor specimens taken from 88 patients with advanced UC treated with ICIs.
Rana McKay, MDAdvanced Urothelial Carcinoma | April 10, 2023
Dr Rana McKay shares how the approval of enfortumab vedotin plus pembrolizumab impacts patients with advanced UC.
Zachary BessetteAdvanced Urothelial Carcinoma | April 4, 2023
Enfortumab vedotin-ejfv with pembrolizumab is now approved for patients with locally advanced or metastatic UC.
Emily MenendezAdvanced Urothelial Carcinoma | March 17, 2023
The TITAN-TCC trial examined the safety and efficacy of nivolumab induction with ipilimumab as an immunotherapeutic boost.
Advertisement
Advertisement
Advertisement